Evidence map›Paper›PMID 27720017›Full record

Trial reportThe Journal of allergy and clinical immunology2016

Distinguishing characteristics of difficult-to-control asthma in inner-city children and adolescents.

Jacqueline A Pongracic, Rebecca Z Krouse, Denise C Babineau, Edward M Zoratti, Robyn T Cohen, Robert A Wood, Gurjit K Khurana Hershey, Carolyn M Kercsmar, Rebecca S Gruchalla, Meyer Kattan and 10 more

Registry-linked trialAbstract readClinical Trial
In one paragraph

Trial report in The Journal of allergy and clinical immunology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01383941 (Asthma Phenotypes in the Inner City), which is not on this map. Cited by 58 papers.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed
9.0field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01383941 completednot on this map

Asthma Phenotypes in the Inner City (ICAC-19)

TypeobservationalSponsorNational Institute of Allergy and Infectious Diseases (NIAID)Ran2011 to 2014Enrolled717ConditionsAsthma, RhinitisArmsGuidelines-based asthma and rhinitis/rhinosinusitis therapy
3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 114 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Cumulative genetic risk for asthma contributes to disease severity in children with asthma.The journal of allergy and clinical immunology. Global · 2026
    Article
  4. Associations between body weight, asthma burden, and type 2 inflammation among under-resourced children.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2026
    Article
  5. Article
  6. Article
  7. Article
  8. Racial differences in odds of asthma exacerbations among Aspergillus fumigatus-sensitized adults with asthma.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2025
    Article
  9. Article
  10. Article
  11. Risk Factors for Acute Asthma Exacerbations in Adults With Mild Asthma.The journal of allergy and clinical immunology. In practice · 2024
    Article
  12. Improving asthma outcomes: Clinicians' perspectives on peripheral airways.The journal of allergy and clinical immunology. Global · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Allergic Asthma in the Era of Personalized Medicine.Journal of personalized medicine · 2022
    Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 13 institutions in 1 country.

Jacqueline A PongracicAnn and Robert H. Lurie Children's Hospital of Chicago, Chicago, Ill. Electronic address: jpongracic@luriechildrens.org.
Rebecca Z KrouseRho Federal Systems Division, Chapel Hill, NC.
Denise C BabineauRho Federal Systems Division, Chapel Hill, NC.
Edward M ZorattiHenry Ford Health System, Detroit, Mich.
Robyn T CohenBoston University School of Medicine, Boston, Mass.
Robert A WoodJohns Hopkins University School of Medicine, Baltimore, Md.
Gurjit K Khurana HersheyCincinnati Children's Hospital, Cincinnati, Ohio.
Carolyn M KercsmarCincinnati Children's Hospital, Cincinnati, Ohio.
Rebecca S GruchallaUniversity of Texas Southwestern Medical Center, Dallas, Tex.
Meyer KattanCollege of Physicians and Surgeons, Columbia University, New York, NY.
Stephen J TeachChildren's National Health System and the George Washington University School of Medicine and Health Sciences, Washington, DC.
Christine C JohnsonHenry Ford Health System, Detroit, Mich.
Leonard B BacharierSt Louis Children's Hospital, St Louis, Mo.
James E GernUniversity of Wisconsin School of Medicine and Public Health, Madison, Wis.
Steven M SigelmanNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Peter J GergenNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Alkis TogiasNational Institute of Allergy and Infectious Diseases, Bethesda, Md.
Cynthia M VisnessRho Federal Systems Division, Chapel Hill, NC.
William W BusseUniversity of Wisconsin School of Medicine and Public Health, Madison, Wis.
Andrew H LiuNational Jewish Health, Denver, and Children's Hospital Colorado and University of Colorado School of Medicine, Aurora, Colo.
National Institute of Allergy and Infectious Diseases · USRho (United States) · USCincinnati Children's Hospital Medical Center · USHenry Ford Health System · USUniversity of Wisconsin–Madison · USBoston University · USChildren's National · USColumbia University · USJohns Hopkins University · USLurie Children's Hospital · USNational Jewish Health · USSt. Louis Children's Hospital · USThe University of Texas Southwestern Medical Center · US

Funding

Transplantation GroupUM2AI117870 · NIAID · RHO FEDERAL SYSTEMS DIVISION, INC. · PI DAVID, GLORIA · 2015 to 2023
$208.1M
Inner City Asthma consortium 3 (ICAC3)UM1AI114271 · NIAID · UNIVERSITY OF WISCONSIN-MADISON · PI GERN, JAMES E., JACKSON, DANIEL J · 2014 to 2021
$79.4M
CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR025780 · NCRR · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2008 to 2011
$61.3M
Colorado Clinical and Translational Sciences InstituteUL1TR001082 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2013 to 2017
$48.0M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
UT Southwestern Center for Translational Medicine (UL1/KL2/TL1)UL1TR001105 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2013 to 2017
$24.5M
Colorado Clinical and Translational Science Institute (UL1)UL1TR000154 · NCATS · UNIVERSITY OF COLORADO DENVER · PI SOKOL, RONALD J. · 2012 to 2013
$20.4M
Clinical and Translational Science Institute at Children's NationalUL1TR000075 · NCATS · CHILDREN'S RESEARCH INSTITUTE · PI GUAY-WOODFORD, LISA MARIE · 2012 to 2015
$13.7M
Multidisciplinary Clinical and Translational Science (MCTS) Program (UL1)UL1TR000150 · NCATS · NORTHWESTERN UNIVERSITY AT CHICAGO · PI LLOYD-JONES, DONALD M · 2012 to 2013
$10.1M
Cincinnati Center for Clinical and Translational Sciences and TrainingUL1TR000077 · NCATS · UNIVERSITY OF CINCINNATI · PI HEUBI, JAMES E. · 2012 to 2014
$9.9M
UT-Southwestern Clinical and Translational Alliance for Research (UT-STAR) (TL1)UL1TR000451 · NCATS · UT SOUTHWESTERN MEDICAL CENTER · PI TOTO, ROBERT DANIEL · 2012 to 2012
$6.3M
NCATS NIH HHS UL1 TR000040NCATS NIH HHS UL1 TR000075NCATS NIH HHS UL1 TR000077NCATS NIH HHS UL1 TR000150NCATS NIH HHS UL1 TR000154NCATS NIH HHS UL1 TR000451NCATS NIH HHS UL1 TR001082NCATS NIH HHS UL1 TR001105NCRR NIH HHS UL1 RR025780NIAID NIH HHS HHSN272200900052CNIAID NIH HHS HHSN272201000052INIAID NIH HHS UM1 AI114271NIAID NIH HHS UM2 AI117870
6 · The paper itself

Abstract

backgroundTreatment levels required to control asthma vary greatly across a population with asthma. The factors that contribute to variability in treatment requirements of inner-city children have not been fully elucidated.

objectiveWe sought to identify the clinical characteristics that distinguish difficult-to-control asthma from easy-to-control asthma.

methodsAsthmatic children aged 6 to 17 years underwent baseline assessment and bimonthly guideline-based management visits over 1 year. Difficult-to-control and easy-to-control asthma were defined as daily therapy with 500 μg of fluticasone or greater with or without a long-acting β-agonist versus 100 μg or less assigned on at least 4 visits. Forty-four baseline variables were used to compare the 2 groups by using univariate analyses and to identify the most relevant features of difficult-to-control asthma by using a variable selection algorithm. Nonlinear seasonal variation in longitudinal measures (symptoms, pulmonary physiology, and exacerbations) was examined by using generalized additive mixed-effects models.

resultsAmong 619 recruited participants, 40.9% had difficult-to-control asthma, 37.5% had easy-to-control asthma, and 21.6% fell into neither group. At baseline, FEV

conclusionsDespite good adherence, difficult-to-control asthma showed little improvement in symptoms, exacerbations, or pulmonary physiology over the year. In addition to pulmonary physiology measures, rhinitis severity and atopy were associated with high-dose asthma controller therapy requirement.

Indexed as

Urban PopulationAdolescentAge of OnsetAnti-Asthmatic AgentsAsthmaBaltimoreChildFemaleHumansLongitudinal StudiesMaleMedical History TakingPovertyProspective StudiesRhinitisSeverity of Illness IndexAnti-Asthmatic Agentsallergen sensitizationasthmaasthma exacerbationsasthma morbidityasthma phenotypeasthma severityChildIgEinner-city asthmapulmonary functionrhinitis

Identifiers

PMID27720017
PMCPMC5379996
OpenAlexW2528622423

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.